A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft

Ostomy Wound Management

Volumn 60, Issue 9, 2014, Pages 26-38

  Sanders, Lee ^a   Landsman, Adam S ^b   Landsman, Arnold ^c   Keller, Nelson ^d   Cook, Jeremy ^e   Cook, Emily ^e   Hopson, Matthew ^f  

^a TEMPLE UNIVERSITY SCHOOL OF PODIATRIC MEDICINE   (United States)

^b CAMBRIDGE HOSPITAL   (United States)

^c Soluble Systems   (United States)

^d Colonial Foot Care ^*  (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f TPMG Orthopedics and Sports Medicine   (United States)

Author keywords

dermal skin substitute; diabetic foot ulcer; human skin allograft; randomized trial; wound healing

Indexed keywords

ADULT; AGED; ALLOGRAFT; ARTIFICIAL SKIN; BIOENGINEERING; CONTROLLED STUDY; DIABETIC FOOT; FEMALE; HUMAN; MALE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRENDS; VERY ELDERLY; WOUND HEALING;

ADULT; AGED; AGED, 80 AND OVER; ALLOGRAFTS; BIOENGINEERING; DIABETIC FOOT; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SKIN, ARTIFICIAL; WOUND HEALING;

EID: 84907062988     PISSN: 08895899     EISSN: 19432720     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes JAMA. 2005;12;293(2):217-228.
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: US Department of Health and Human Services;2014.
3. Goodridge D, Trepman E, Sloan J, Guse L, Strain L, McIntyre J, Embil JM. Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot Ankle Int. 2006;27(4):276-280.
4. Driver VR, Fabbi, M, Lavery LL, Gibbons G. The cost of diabetic foot: the economic case for the limb salvage team. J Vasc Surg. 2010;52 (3 suppl):17S-22S.
5. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention;2011.
6. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Basis for prevention. Diabetes Care. 1990;13(5):513-521.
7. McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecoraro RF. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care. 1995;18(2):216-219.
8. Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care. 1999;22(1):157-162.
9. Organogenesis, Canton, MA. Product information. Dermagraft® Human Fibroblast-Derived Dermal Substitute. Directions For Use.
10. Marston WA, Hanft J, Norwood P, Pollak R, Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care. 2003;26(6):1701-1705.
11. CFR - Code of Federal Regulations Title 21, PART 1271 - Human Cells, Tissues, and Cellular and Tissue-Based Products, Sec. 1271.10;. Available at: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ CFRSearch.cfm?fr=1271.10. Accessed August 6, 2014.
12. Snyder RJ. Treatment of nonhealing ulcers with allografts. Clin Dermatol. 2005;23(4):388-395.
13. Bolivar-Flores YJ, Kuri-Harcuch W. Frozen allogeneic human epidermal cultured sheets for the cure of complicated leg ulcers. Dermatol Surg. 1999;25:610-617.
14. Landsman AS. A comparison of the types and quantities of collagen found in Apligraf, DermaGraft, and Theraskin. Abstract presented at the 23rd Annual Symposium on Advanced Wound Care. Orlando, FL. April 17-20, 2010.
15. Landsman AS, Cook J, Cook E, Landsman AR, Garett P, Yoon J, et al. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers. Foot Ankle Spec. 2011;4(1):29-41.
16. Gilman TH. Parameter for measurement of wound closure. WOUNDS. 1990;2(3):95-101.
17. DiDominico L, Emch KJ, Landsman AR, Landsman A. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. WOUNDS. 2011;23(7):184-189.
18. Harding K, Sumner M, Cardinal M. A prospective, multicenter, randomized controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J. 2013;10(2):132-137.